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Despite improvements in treatment, the 5-year survival for metastatic colorectal cancer remains poor. Novel approaches such as
gene immunotherapy are being investigated to improve treatment. Retroviral gene transfer methods have been shown to transduce
primary human T lymphocytes effectively resulting in the expression of therapeutic genes. However, a number of defects have been
identified in T lymphocytes isolated from patients bearing tumour, which may have critical implications for the development of gene-
targeted T cells as an anticancer therapy. To address this issue, primary T lymphocytes were isolated from patients with advanced
colorectal cancer and tested for their ability to be transduced and to express subsequently a chimeric immune receptor consisting of
a single-chain antibody fragment antigen-binding moiety specific for carcinoembryonic antigen (CEA) fused to the T cell receptor
(TCR) CD3z chain. In 10 out of 10 patients, T lymphocytes were transduced, expanded in the absence of selection and tested for
functional activity against CEA-expressing tumour cells. In each case, functional-specific cytotoxic activity was observed. Negligible
activity was found in control cultures. This study highlights the feasibility of patient-derived T lymphocytes as a source of immune cells
for autologous gene immunotherapy approaches.
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Colorectal cancer affects approximately 300000 people in Europe
and the US each year (Midgley and Kerr, 1999), accounting for
20–30000 deaths in the UK alone (Curley and Vecchio, 1998).
Surgery can cure selected patients with liver metastases (DeMatteo
et al, 2000; Biasco and Gallerani, 2001). However, despite
continued advances in systemic treatment, the overall 5-year
survival has not improved significantly for advanced colorectal
disease (Midgley and Kerr, 1999).
Our aim is to utilise the power of the immune system as a novel
form of cancer therapy. Gene therapy techniques have been
developed to modify T lymphocytes in order to target and lyse
colorectal tumour cells through the development of chimeric
immune receptors (CIRs) (Hombach et al, 1999; Nolan et al, 1999;
Beecham et al, 2000; Daly et al, 2000). CIRs are composed of
antigen binding domains, usually derived from single-chain
antibody fragments (scFv) (Hawkins et al, 1998), fused to the
cytosolic domains of important signalling receptors (Gross et al,
1989) (Figure 1A). Our present work has focused upon the
targeting of carcinoembryonic antigen (CEA) through a CEA-
specific scFv fused to the CD3z chain. CD3z is thought to play the
predominant role in T-cell signalling resulting in T-cell effector
activity (Haynes et al, 2001). Binding of CEA by the CEA-specific
CIR generates downstream activation signals resulting in cytokine
production and target cell cytotoxicity in the absence of the usual
restrictive mechanisms required for T-cell activation (Hombach
et al, 1999; Nolan et al, 1999; Beecham et al, 2000; Daly et al, 2000).
This approach results in the generation of large numbers of
antigen-specific T cells. Importantly, since the CIRs recognise
whole-protein antigens, tumour cells should not be able to
avoid immune detection by the downregulation of immunoregu-
latory molecules such as major histocompatibility (MHC)
molecules.
The CIRs used in this study were either an anti-CEA-specific
scFv, MFE23 (derived by phage display technology) (Chester et al,
1994; Begent et al, 1996) or a control scFv (anti-neural cell
adhesion molecule (NCAM)) (D29) (Whittington et al, 2001) fused
to the human CD3z protein. Both receptors have been shown to be
active when introduced into primary human T lymphocytes
derived from healthy donors (Gilham et al, 2002). Importantly,
in T cells derived from these normal, healthy donors, the presence
of soluble CEA did not inhibit the cytolytic activity of the gene-
modified T lymphocytes suggesting that high-serum CEA should
not interfere with the activity of the anti-CEA CIR in patients.
However, important questions remain concerning the viability
of this approach for clinical use. A number of studies have
demonstrated that T lymphocytes isolated from tumour-bearing
mice (Mizoguchi et al, 1992) and patients (Bukowski et al, 1998)
are dysfunctional owing to altered expression of key proteins
including members of the CD3 complex. T lymphocytes isolated
from patients with advanced melanoma (Saito et al, 2000), and
head and neck cancer (Hoffman et al, 2002) have also been shown
to be more susceptible to spontaneous apoptosis thereby
potentially compromising the patient’s own immune competence.
Furthermore, tumour-infiltrating lymphocytes isolated from
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scolorectal hepatic metastases have been shown to have reduced
CD3z chain expression and, upon expansion, lack tumour-specific
lytic activity (Yoong and Adams, 1998). In view of this work and to
further determine the viability of our approach in a clinical setting,
T lymphocytes were isolated from the peripheral blood of patients
with advanced colorectal disease (hepatic colorectal metastases) in
order to determine whether they could be efficiently gene modified
to express a chimeric immune receptor. Subsequently, the
functional activity of the CIR in T lymphocytes was assessed
through its ability to induce cytolytic activity when challenged with
tumour cell lines in vitro.
MATERIALS AND METHODS
Reagents
All chemical reagents except where stated were purchased from
Sigma (Dorset, UK). Anti-CD3e (OKT3) was purchased from
Orthobiotech (USA) and anti-hCD28 from R&D Systems (Min-
neapolis, MN, USA). Chiron (Amsterdam, The Netherlands)
supplied the recombinant human IL-2.
Cell culture
All cell culture materials were obtained from Life Sciences (Paisley,
Scotland). The human CEA-positive cell lines MKN45K (human
gastric carcinoma, kindly provided by Dr J Embleton, PICR),
LS174T (human colon adenocarcinoma, ECACC No. 87060401),
LoVo (human colon adenocarcinoma, ECACC No. 87060101),
NCAM positive SK-N-BE (human neuroblastoma, ATCC No.
CCRL-2271), PG13 retroviral producer cells (Miller et al, 1991)
and HeLa (human cervix epithelial carcinoma, ECACC No.
93021013) cell lines were all cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% foetal bovine serum (FBS, Life
Technologies, Paisley, Scotland). Patient T lymphocytes were
cultured in T-cell media (RPMI 1640, 25mM HEPES, 2mM
glutamine and 5 10
5 2-mercaptoethanol with the addition of
10% FBS). All cells were maintained in a 371C5 %C O 2/air
incubator.
Production of recombinant receptors encoding CIRs
Stable PG13 cell lines producing either rkat.MFE23.CD3zTDGA.IR-
ES.EGFP and rkat.D29.CD3zTDGA.IRES.EGFP recombinant retro-
viruses have been previously described (Gilham et al, 2002). These
vectors consist of the MFE23 scFv (specific for CEA) or the D29
scFv (specific for NCAM) fused to the CD3z receptor protein with
the enhanced green fluorescent protein (EGFP) coexpressed by
means of an internal ribosome entry site (IRES) element. Cell
culture media were aspirated from PG13 cell monolayers
(approximately 70–80% confluent) and replaced with T-cell
media. Retrovirus was collected after an overnight incubation
and then filtered through a 0.45mm filter prior to its use in
transduction. T-cell media were replaced onto the PG13 monolayer
with more virus collected and filtered after an overnight
incubation for second and subsequent transductions.
Patient details
All patients selected were due to undergo hepatic resection for
colorectal liver metastases and were consented for the purposes of
this study as approved by North and South Manchester Ethics
committees. The median age of the patients was 66 years (range
42–73 years, mean 65.279.9 years). No patient had received any
form of chemotherapy for at least 1 month prior to T lymphocyte
harvest. Preoperative serum CEA levels and operations performed
are listed in Table 1.
Patient T lymphocyte isolation and transduction
Approximately 20ml of venous blood was obtained from each
patient approximately 2–3 weeks prior to hepatic resection.
Heparinised venous blood was diluted 1:1 ratio with serum-free
RPMI 1640 media and mononuclear cells isolated by Ficoll-density
gradient centrifugation (Ficoll–Histopaque (density 1077gl
 1)
Sigma, Dorset, UK). Monocytes were depleted by adherence to
plastic by culture for 1h in tissue culture flasks at 371C.
Nonadherent lymphocytes were isolated and activated in 6-well
nontissue culture plates precoated antibody (OKT-3 and anti-
CD28) with 100IUml
 1 interleukin-2 (IL-2) for at least 3 days.
After activation, T lymphocytes were ficolled to remove dead cells,
washed and counted. 1–4.5 10
6T lymphocytes were mixed with
PG13-derived retroviral supernatant and polybrene (6mgml
 1)
in a 50ml falcon tube and centrifuged for 2–3h at 1400 g.
Mock-transduced cells were mixed with T-cell media with
polybrene instead of retroviral supernatant and centrifuged. After
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Figure 1 Expression of chimeric receptor proteins in primary human T
lymphocytes derived from patients with advanced colorectal cancer. (A)
The specificity of the scFv used in these studies. (B) Chimeric receptor
transduced and mock patient T lymphocytes, at time of cytotoxicity assays,
were lysed with RIPA and subjected to reducing or nonreducing SDS–
PAGE and transferred to nitrocellulose filters. Blots were probed with anti-
CD3z Mab (1:1000 dilution, Pharmingen, Oxford, UK) with a secondary
antibody of anti-mouse Fc-HRP conjugate (1:2000) and immunoreactive
bands visualised using ECLt (Amersham, UK). Under reducing conditions,
the endogenous CD3z protein was identified as a 16kDa band in all
samples with the chimeric receptors clearly identified as single immuno-
reactive bands at the predicted molecular mass of 43kDa. Chimeric
homodimers (86kDa) and heterodimers (60kDa) formed with the
endogenous CD3z were identified along with CD3z homodimers (32
kDa) under nonreducing conditions.
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scentrifugation, T lymphocytes were cultured overnight at
5 10
5ml with 100IUml
 1 IL-2. Centrifugal transduction was
repeated the next day and the resulting cell populations were
maintained at 5 10
5cellsml
 1 in 100IUml
 1 IL-2. Fresh media
and IL-2 were added every 2–3 days.
Flow cytometry
Cells were washed with phosphate-buffered solution (PBS)/2%
bovine serum albumin (BSA) and then resuspended in saturating
concentrations of antibody (anti-CD3e, CD4, CD8 and suitable
isotype controls (all R-Phycoerythrin conjugated) purchased from
Pharmingen, Oxford, UK) on ice for 30min. Cells were then
washed twice with PBS/2% BSA, fixed in 2% paraformaldehyde and
analysed using a FACscan (Becton Dickenson, CA, USA) with
winMDI version 2.8 analysis software.
Cytotoxicity assays
Three days prior to cytotoxicity assay, T lymphocytes were
cultured in low IL-2 (20IUml
 1) to reduce background lympho-
kine-activated killer (LAK) activity (Gilham et al, 2002). An 8-h
chromium release assay was performed as previously described
(Gilham et al, 2002) with effector:target ratios from 50:1 to
6.25:1. Maximal release was obtained by coculture with 100ml2 %
Triton X-100/PBS and spontaneous release by target cell culture in
media alone. Percentage-specific lysis was determined by the
following formula:
ðobservedrelease   spontaneousreleaseÞ
ðmaximumrelease   spontaneousreleaseÞ
 100
Western blotting
Patient T lymphocytes were washed with PBS and lysed in
RIPA buffer (150mM NaCl, 1% NP-40, 0.5% deoxycholic acid,
0.5% sodium dodecyl sulphate (SDS) and 50mM Tris-Cl pH 8.0)
at the time of cytotoxicity assay and stored at  701C. Approxi-
mately 5 10
5 cells were separated by standard techniques
using SDS/PAGE on 10% resolving gels (Lamelli, 1970). Hybondt
ECLt nitrocellulose membrane (Amersham Pharmacia Biotech,
Buckinghamshire, UK) was used for blots with anti-CD3z
(clone 8D3) at 1:1000 dilution (Pharmingen, Oxford, UK) and a
secondary of sheep anti-mouse HRP antibody at 1:2000
Table 1 A summary of patient details, including operation and preoperative serum CEA levels, with T lymphocyte population phenotypes after retroviral
transduction and expansion
Patient
(age in years)
ScFv fused to
CD3fTDGA
Preoperative
CEA (lgl
 1) Operation % CD3+
% CD3+,
GFP+
% CD8+,
GFP+
% CD4+,
GFP+
Ratio of
transduced
CD8+:CD4+
Ratio of
total
CD8+:CD4+
T cells
1 (70) Mock 35 Left hepatectomy 99 0 0 0 F 11.5:1
MFE23 99 20 12 3 4:1 8.9:1
D29 99 15 17 3 5.7:1 9.1:1
2 (66) Mock 6 Right hepatectomy 99 0 0 0 F 4.2:1
MFE23 99 5 5 2 2.5:1 4.9:1
D29 99 7.5 7 1 7:1 4.5:1
3 (64) Mock 1 Right hepatectomy 96 1 0 0 F 2.3:1
MFE23 91 21 19 16 1.2:1 1.5:1
D29 90 13 9 6 1.2:1 1.5:1
4 (70) Mock 9 Right hepatectomy 99 0 0 0 F 1.9:1
MFE23 94 21 19 8 2.4:1 2.1:1
D29 97 9 11 5 2.2:1 2.2:1
5 (42) Mock 155 Left hepatectomy
+segmentectomy
88 1 2 1 2:1 1.3:1
MFE23 93 33 17 13 1.0:1 1.4:1
D29 89 23 20 14 1.4:1 1.4:1
6 (73) Mock >1500 Right Hepatectomy 89 0 3 0 F 10:1
MFE23 88 11 10 1.5 6.7:1 4.3:1
D29 87 4 5 1 5:1 7.6:1
7 (78) Mock 6 Inoperable – extra-hepatic
disease
99 0 0 0 F 1.9:1
MFE23 99 23.9 15.6 7.9 2:1 1.8:1
D29 99 2 1 0.3 3.3:1 1.8:1
8 (66) Mock 4 Inoperable – extra-hepatic
disease
99 0 0 0 F 8.8:1
MFE23 99 19.9 15.5 1.9 8.1:1 7.0:1
D29 99 2 1.3 0.2 6.5:1 8.4:1
9 (66) Mock 24 Right hepatectomy 99 0 0 0 F 7.4:1
MFE23 99 25 17 3 5.7:1 8.5:1
D29 99 20 19 2 9.5:1 8.2:1
10 (57) Mock 156 Left hepatectomy 99 2 0 0 F 4.2:1
MFE23 99 14 18 3 6:1 4.0:1
D29 99 9 10 1 10:1 4.6:1
All 10 patients recruited were due to undergo surgery for colorectal hepatic metastases. All the metastases removed or biopsed were confirmed as adenocarcinoma of colorectal
origin by histological examination. T lymphocytes were isolated from these patients 2–3 weeks prior to surgery and were transduced with recombinant retroviruses encoding
either MFE23.CD3zTDGA or D29.CD3zTDGA chimeric receptors. After expansion using an IL-2-based protocol, the T lymphocyte populations were analysed for the
expression of the EGFP marker gene and for the surface markers CD3, CD4 and CD8 by staining with PE-conjugated antibodies and subsequent flow cytometric analysis using a
FACscan (Becton Dickenson) with winMDI software.
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sdilution (Sigma, Dorset, UK). Visualisation was performed
using ECLt reagents (Amersham Pharmacia Biotech,
Buckinghamshire, UK).
Tumour cell survival assay
Adherent tumour target cell lines (MKN45K, LS174T, LoVo and
HeLa) were plated at a density of 5000 cells in 100ml of T cell
media per well of flat-bottomed 96-well plates. These cells were
allowed to adhere for 3h at which point a further 100ml of T-cell
media containing either varying numbers of transduced or control
T lymphocytes or culture medium alone was added to the target
cells to generate a final volume of 200ml. In some experiments, IL-2
was added to a final concentration of 100IUml
 1. After a period of
coculture, the supernatant containing nonadherent cells was
removed and the remaining cells cultured in DMEM with 10%
FBS without IL-2 for a further 5–6 days. The culture medium was
aspirated, the cells washed once with PBS and 100ml of DMEM
with 10% FBS containing a 40-fold dilution of Wst-1 reagent
(Roche, Surrey, UK). At suitable time points, the optical density of
the wells was determined using an ELISA plate reader (Molecular
Devices, Sunnydale, CA, USA) set at 450–650nm. Maximal cell
growth was determined from the optical density reading of tumour
cells cultured without T lymphocytes and minimal cell growth was
determined from tumour cells cultured without T lymphocytes and
lysed with 50ml of 2% Triton X-100/PBS. Relative tumour cell
growth was estimated by the following equation:
ðtestcellgrowthOD   minimalcellgrowthODÞ
ðmaximalgrowthOD   minimalcellgrowthODÞ
 100
RESULTS
Transduction of patient T lymphocytes
Twenty millilitres of venous blood was obtained from patients 1 to
10 two to three weeks prior to the date of surgery. T lymphocytes
were isolated and activated using immobilised anti-CD3 and anti-
CD28 antibodies. After 3 days of antibody activation, 5–10 10
6
viable T cells were counted by trypan blue exclusion for each
patient indicating that in 10 out of 10 samples, T lymphocytes were
successfully activated. Transduction with retroviruses encoding
the anti-CEA CIR, MFE23.CD3zTDGA or the anti-NCAM CIR,
D29.CD3zTDGA (Figure 1A) was performed using centrifugation
in the presence of polybrene. After transduction, patient T
lymphocytes were expanded in number by 5–10-fold over the
next 7–21 days in the presence of 100IUml
 1 of IL-2 (data not
shown). Flow cytometry analysis confirmed the cell populations to
consist largely of CD3-positive T lymphocytes (87–99%, Table 1).
The IL-2-based expansion protocol supported the growth of the
polyclonal T lymphocyte populations, although there was a relative
predominance of CD8+ over CD4+ T cells. The lowest ratio of
CD8:CD4 was 1.5:1, while ratios in excess of 10:1 were recorded
for two donors.
The level of retroviral transduction was estimated through the
expression of the EGFP marker gene. A degree of heterogeneity
was also observed with the levels of retroviral transduction varying
between 2 and 33% (Table 1). In each patient sample, the ratio of
transduced CD8 to transduced CD4 cells reflected the overall ratio
of total CD8 to CD4T cells in the total population suggesting there
to be little bias in the susceptibility of either T-cell sub-type to
transduction by the PG13-derived retroviruses.
Chimeric immune receptor expression in T lymphocytes was
confirmed by Western blotting (Figure 1B). Nonreducing Western
blots identified the formation of CIR homodimers and also
heterodimers formed between the CIR and wild-type CD3z.
Reducing Western blots demonstrated an immunoreactive band
at the predicted molecular mass of the CIR (43kDa) with the native
CD3z protein present as a 16kDa immunoreactive band.
Specific cytotoxicity of CEA-positive cells by patient-
modified T lymphocytes
MFE23.CD3zTDGA-modified lymphocytes from patient 1 demon-
strated specific cytotoxic activity against the CEA-expressing
gastric tumour cell line MKN45K and the colon adenocarcinoma
LS174T cell line. Negligible cytotoxicity was observed when
NCAM-targeted (D29.CD3zTDGA) and mock-transduced T lym-
phocytes were cocultured with the MKN45K or LS174T cell lines
(Figures 2A and B). Specific CEA-targeted lysis was found to be
increased by at least seven-fold over that of nontargeted
lymphocytes.
The specificity of cell killing was confirmed by the cytotoxic
activity of D29.CD3zTDGA-transduced T lymphocytes against
NCAM-positive neuroblastoma SK-N-BE target cells (Figure 2C).
In this case, low background activity was found when CEA-
targeted (MFE23.CD3zTDGA) and mock-transduced T lympho-
cytes were cultured with CEA-negative SK-N-BE cells (Figure 2C).
HeLa cells (NCAM- and CEA-negative) were used to demonstrate
equivalent nonspecific killing by all three populations thereby
confirming that the specific killing observed was because of CIR
activity and not because of any altered killing properties of the
individual lymphocyte populations (Figure 2D). The level of
retroviral transduction (as assessed by the expression of EGFP)
was 20% in the MFE23.CD3zTDGA CIR-expressing population
generated from patient 1. This figure indicates that the maximal
transduced effector to target ratio was 10:1 with highly specific
cytolytic activity observed down to a ratio of 1.25 transduced
effector cells per target (Figure 2A). In the case of NCAM-targeted
cells (SK-N-BE, Figure 2C), the proportion of D29.CD3zTDGA-
expressing cells was estimated to be 15%, hence, the transduced
effector to target ratio was maximally 7.5:1 with clear specific
cytolytic activity at the lowest ratio tested (0.9 transduced T cells
per target cell).
Specific, targeted cytotoxicity was subsequently demonstrated
for the remaining five patient lymphocyte samples against
MKN45K gastric carcinoma cells (Figure 3). In each case, specific,
dose-dependent killing was observed. Furthermore, in each case,
very low background levels of killing were observed
(D29.CD3zTDGA and mock-transduced lymphocytes). This prob-
ably reflects the period of preculture in low concentrations of IL-2
reducing nonspecific cytokine-mediated killing activity. Equivalent
specific lysis was observed between the various transduced cell
populations when tested against CEA-negative, NCAM-negative
target cells indicating there to be no difference in the overall killing
activity of the modified or nonmodified T lymphocyte populations
(data not shown).
A consideration of the level of retroviral transduction (as
assessed by EGFP expression) did not appear to provide a clear
relation between the levels of expression of the CIRs with the
observed CIR-mediated cytotoxic activities. There was maximally a
6.6-fold difference between these six patient samples in retroviral
transduction frequency, yet the cytotoxic activity varied only 1.6-
fold. It was clear that the lowest level of transduction correlated
with the weakest cytolytic activity (Patient 2; 5% CD3+, GFP+;
20.1% specific killing). However, there appeared little difference in
cytolytic activity in these populations once a transduction level of
20% had been achieved.
Tumour cell survival after coculture with gene-modified
T lymphocytes
Short-term assessments of cytolytic activity clearly demonstrated
that CIR-expressing T-cell populations were functional against
protein antigen targets in an MHC-independent manner. In an
Retroviral transduction of patient T cells
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sattempt to investigate and understand the functionality of these
gene-modified cell populations further, and in an effort to quantify
the overall efficiency of the targeted gene modified cells,
longer-term tumour cell survival assays were used to assess the
effectiveness of these T cells. Adherent tumour cell lines were
cocultured with nonadherent T lymphocytes for set periods of
time, after which the nonadherent cells were removed and the
tumour cells cultured in media without cytokines to ensure that
any remaining T cells would not survive. Five to six days, later, the
growth of the tumour cells was assessed using an MTT-based assay
(Mosmann, 1983).
Multiple cell lines were used in order to examine the activity of
the anti-CEA-targeted T cells. The CEA-expressing human colon
adenocarcinoma lines (LS174T and LoVo) as well as the gastric
carcinoma cell line (MKN45K) were tested as targets along
with HeLa cells used as a control since they do not express
CEA. This subsequent work utilised T lymphocytes generated
from four further patients (7–10, Table 1). The results depicted
in Figure 4 represent the activity of cells generated from Patient 1
0 and are representative of experiments performed with
Donors 7–10.
The first observation was that the cell lines used displayed a
differential degree of susceptibility to coculture with transduced
or control T lymphocytes. HeLa cells proved to be the most
sensitive in that very low levels of target cell survival were recorded
when cocultured for 24h in the presence of T cells at an
effector:target ratio approaching 1:1 (Figure 4D). However, it
was clear that there existed no difference in the sensitivity of HeLa
cells to either transduced or nontransduced T cells, indicating that
there was equivalent nonspecific killing activity between the T-cell
populations in agreement with the results observed in chromium
release assay. The specific effect of T-cell targeting was observed
in assays using CEA-expressing tumour cell lines. In each case,
tumour cell survival was reduced in a dose-dependent manner
when the target cells were cocultured with MFE23.CD3zTDGA
T-cell populations as compared to either NCAM-targeted or
control nontransduced T cells (Figure 4A–C). There was a clear
difference in target cell growth observable at effector:target ratios
of 10:1, which represented a transduced effector:target ratio of
1.4:1. However, only at the highest cell dose (80:1 total cells,
11.2:1 transduced effector:target ratio) there was no tumour
cell growth observed by all three target cell lines after a 24-h period
of coculture. The susceptibility of the gastric (MKN45K) and
adenocarcinoma (LoVo and LS174T) cell lines to nonspecific
killing was reduced compared to that of HeLa cells. However,
in the case of LoVo and LS174T cells, the highest dose of
nontargeted control T cells resulted in a reduction in target cell
survival to levels approximately 40% of maximal (Figures 4A
and C). For MKN45K target cells, there appeared to be an
equivalent degree of antitumour activity in targeted
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Figure 2 Chimeric receptor-expressing T lymphocyte populations demonstrate antigen-specific killing of tumour cell lines. T lymphocytes derived from
Patient 1 expressing either the MFE23.CD3zTDGA (’) or the D29.CD3zTDGA (m) chimeric receptors or control mock-transduced T cells (~) were
cocultured with 5000
51Cr-labelled target cells per well at the indicated effector:target ratios. (The transduced effector:target ratio based upon EGFP
fluorescence is also presented.) After 8h, 100ml of media was harvested and analysed for released
51Cr label (Topcount, Packard, Berkshire, UK). Maximal
lysis was determined by lysis of target cells by 2% Triton X-100/PBS. Target cell lines used were MKN45K (A), LS174T (B), SK-N-BE (C) and HeLa (D).
The results presented are the mean7s.d. of triplicate wells.
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s(MFE23.CD3zTDGA) and nontargeted (D29.CD3zTDGA and
mock-transduced T cells) at the maximum dose of effector cells
(Figure 4B). Microscopic examination of the culture wells
confirmed that large adherent tumour cells were present in the
wells identified as having metabolic activity within the assay with
few lymphocytic cells present. This indicated that attached
lymphocytes made a minimal contribution to the metabolic
activity of the wells in agreement to similar assays performed
elsewhere (Hombach et al, 2001).
The inclusion of IL-2 during the period of coculture drastically
enhanced the effectiveness of target cell killing. For control HeLa
cell targets, a maximal repression of target cell growth was
observed at an effector:target ratio of 20:1 compared to a ratio of
80:1 required in the absence of this cytokine. Once again, there
was little difference between the effectiveness of each T-cell
population in repressing HeLa cell growth (Figure 4H). A similar
degree of enhanced antitumour activity was recorded after
coculture of CEA-expressing cell lines with the T-cell populations.
Maximal tumour cell growth repression was found at lower doses
of effector cells than in the absence of IL-2. Total repression was
found at effector:target ratios of 20:1 (2.8 transduced
MFE23.CD3zTDGA cells:1 target) for both LS174T and MKN45K
cells, while the low dose of 2.5:1 (0.4 transduced cells per effector
target) resulted in maximal LoVo cell killing. The specificity of
activity was maintained with a clear difference in the cytolytic
activity of targeted and nontargeted (NCAM and mock-transduced
cells) being evident (Figures 4E–G). However, enhanced non-
specific, cytokine-driven killing activity was observed against
each cell line since a total repression of tumour cell growth
occurred at lower effector doses than that observed in the absence
of IL-2.
DISCUSSION
Recent studies have shown that T lymphocytes can be redirected
against cancer cell lines using CEA as a target antigen through the
use of CIRs expressed in T cells isolated from healthy donors
(Nolan et al, 1999; Beecham et al, 2000; Daly et al, 2000; Hombach
et al, 2000). In our study, the chimeric receptor consisted of an
extracellular antigen-binding domain (scFv) specific for CEA
(Chester et al, 1994; Begent et al, 1996), attached to the CD3z
component of the T-cell receptor complex. This CIR has already
been demonstrated to be effective in initiating cytokine secretion
and the cytotoxic activities of normal donor T lymphocytes
(Gilham et al, 2002).
In the light of published work demonstrating the dysfunctional
properties of T lymphocytes isolated from patients with a cancer
load (Rosenberg et al, 1994; Bukowski et al, 1998; Yoong and
Adams, 1998), the aims of this project were to assess whether the
conditions used to activate and transduce T lymphocytes from
normal donors were equally effective in T lymphocytes from
patients with advanced colorectal cancer. In addition, it is
important to evaluate whether CIR crosslinking in the presence
of antigen would generate a response in patient cells similar to that
of normal donors.
Ten patients with advanced colorectal cancer were recruited
into this study. T lymphocytes were successfully transduced
with efficiencies ranging from 2 to 33% (mean 1579%, n¼20)
for all viruses and from 5 to 33% (mean 19.477.8%) for
MFE23.CD3zTDGA-transduced T cells (Table 1). It is clear that
higher levels of transduction are preferable particularly with
respect to use in a clinical context. Protocols have been devel-
oped that have reported high-level gene transfer using longer
antibody-mediated preactivation periods (Movassagh et al,
2000), through the use of retronectin to enhance infection
(Hanenberg et al, 1996) or by preloading plates with retrovirus
(Kuhlcke et al, 2002). The levels of retroviral transduction
generated here represent those achieved using a short period
of centrifugation (spin-fection) and is adaptable to transduction
on a large scale. An over-riding issue concerns the development
of such protocols into a clinically applicable process using
good manufacturing process (GMP) guidelines. Clinical trials
using chimeric receptor expressing T lymphocytes against
HIV (Mitsuyasu et al, 2000) and current trials using plasmid-
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Figure 3 Antigen-specific cytotoxicity mediated by chimeric receptor expressing T lymphocytes generated from five patients with advanced colorectal
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Retroviral transduction of patient T cells
AJ Sheen et al
1124
British Journal of Cancer (2003) 88(7), 1119–1127 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
stransfected T cells expressing chimeric receptors (Jensen et al,
2000) have demonstrated the feasibility of this approach, and
efficient gene-transfer protocols are now being developed based
upon this experience. As a result, the optimal protocol may or may
not feature some of the methods described above. As such, the use
of a spin-fection protocol permitted levels of transduction that
were suitable to permit the analysis of CIR activity in primary
patient T cells.
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Figure 4 Tumour target cell survival after coculture with targeted and nontargeted T lymphocytes. Adherent tumour cell lines (5000) were cultured with
either MFE23.CD3zTDGA (’) or the D29.CD3zTDGA (m) chimeric receptors or control mock-transduced T cells (~), generated from Patient 10, at the
indicated effector:target ratios (The transduced effector:target ratio based upon EGFP fluorescence is also presented.) in wells of flat-bottomed 96-well
plates in a final volume of 200ml. Interleukin-2 was added to some wells at a final concentration of 100IUml
 1 (E–H). After 24h, media and nonadherent
cells were removed and replaced with target cell culture medium without T-cell cytokines. After a further 5 days of culture, the wells were aspirated, washed
with PBS and 100ml of DMEM/10% FBS containing a 1:40 dilution of wst-1 reagent (Roche, Surrey, UK). The optical density of the wells was assessed at
450–650nm using an ELISA plate reader (Molecular Devices, Sunnydale, CA, USA). Maximal tumour cell growth was assessed from the optical density of
wells containing tumour cells only and minimal growth determined from wells containing tumour cells lysed with 2% Triton X-100. Target cell lines used
were MKN45K (A), LS174T (B), SK-N-BE (C) and HeLa (D). The results are presented as the mean7s.d. values of quadruplicate wells.
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sAfter transduction, all 10 of the patient T-cell samples were
expanded using an IL-2-based expansion protocols. The level of
expansion reported here using IL-2 alone ranged from five- to 10-
fold above the starting number. For clinical application, an ideal
scenario would involve the generation of large numbers of T cells
from, for example, a single blood collection or leucophoresis. It
would be anticipated that a larger scale expansion of patient-
derived lymphocytes would be required. Preliminary studies have
shown that the inclusion of soluble antibodies (OKT3 and anti-
CD28) with IL-2 enhanced the level of expansion above that with
IL-2 alone (data not shown). These experiments have used
standard media with FBS and, as such, do not represent conditions
proposed for use in a clinical situation. Our efforts are now
directed to investigating the growth of patient-derived T lympho-
cytes using GMP conditions reported for the maximal growth of T
lymphocytes elsewhere (Carlens et al, 2000). However, the fact that
all 10 patient samples were successfully transduced and expanded
was encouraging, considering the reported frailties of patient-
derived T lymphocytes (Mizoguchi et al, 1992; Rosenberg et al,
1994; Bukowski et al, 1998).
The CIR-bearing cell populations responded to antigen present
on cell lines through specific target cell lysis in an MHC-
independent manner. Importantly, even in the T-cell population
with the lowest transduction level, significant antigen-specific
cytotoxic activity was observed. Interestingly, increasing the level
of retroviral transduction did not result in an increasing functional
cytotoxic activity. Once a transduction level of 20% had been
achieved, there appeared to be little increase in overall antigen-
specific cytotoxicity as assessed by chromium release assay. These
observations, albeit on a restricted number of transduced patient
samples, indicates that more complicated factors may be at work.
Further work is required to determine whether the killing activity
generated by the transduced population is mediated by a few
modified cells acting with high efficiency or whether the majority
of CIR-expressing cells are acting at lower efficiency in order to
generate the antigen-specific cytotoxicity observed here. This is
important because further development of this approach may
require optimisation of the receptor in order to produce a stronger
response in cells where killing efficiency is low, while a
modification to T-cell activation and culture conditions may be
required to generate a greater number of highly cytotoxic T cells.
Interestingly, the specific production of interferon gamma from
the T-cell cultures in the presence of antigen was less clearcut.
Although there was evidence of specific cytokine production from
some donors, in others there was either high background or poor
levels of overall cytokine secretion (data not shown). The reasons
for this are unclear, but were not related to cytotoxic activity.
An alternative to the chromium release assay was used to further
investigate the potential of the gene-modified T lymphocytes.
Tumour cell survival was assessed after a period of coculture with
T cells. These assays potentially assess the longer-term interactions
of effector and target cells, which may affect target cell survival
through processes such as the induction of apoptosis through
cytokine activity or death receptor activation.
An important observation was the fact that there was a
difference in the overall sensitivity of the individual tumour cell
lines to coculture with allogeneic T cells. This feature may be
reflected in vivo where tumours would most likely show a variation
in susceptibility to T lymphocyte activity. HeLa cells proved to be
most sensitive to nonspecific killing in the tumour cell survival
assay. In comparison, the colon adenocarcinoma and gastric cell
lines were more resistant to nonspecific killing, although these
cell lines were efficiently targeted by anti-CEA CIR-expressing T-
cell populations. Coculture in the presence of IL-2 drastically
enhanced both the nonspecific and specific killing activities of the
T-cell populations. A total repression of target cell growth was seen
in effector:target ratios as low as 2.8 transduced T cells per target
for MKN45K and LS174T cells and as low as 0.4 transduced cells
per target for LoVo cells. It is not clear whether the enhanced
cytolytic activity is through enhanced lymphokine-activated killer
(LAK) activity of the T cells resulting in the T cells being more
active in cytolytic assays or whether the IL-2 was acting as a
survival factor effectively enhancing the survival of the T cells
(which had previously been expanded in IL-2), thereby permitting
an enhanced killing activity. In either case, it is clear that cytokine
help is potentially of crucial importance in the clinical setting
through the reduction of the number of T cells required to target a
tumour mass.
From the in vitro data presented here, the addition of IL-2
resulted in at least a four-fold decrease in the cell number required
to effect a total repression of tumour cell line growth. It is
impossible to apply in vitro assay results directly to the problem of
dealing with tumour masses in vivo. However, this work suggests
that for CIR-expressing T lymphocytes to function in a practical
form in vivo, the CIR-modified cells will require some help in the
form of survival or activation signals. These signals may take the
form of infusions of IL-2. However, IL-2 administration is
associated with toxicity. Alternative studies in our own group
have investigated the ability of antiapoptotic genes to act as
survival factors which could be expressed from a single retroviral
construct (Eaton et al, 2002). Recent developments in CIRs have
also involved the generation of receptors composed of the CD3z
domain fused to the CD28 receptor signalling chain (Hombach
et al, 2001; Maher et al, 2002). These fusion receptors generate
both a cytotoxic response and a costimulatory signal (and
therefore IL-2 production) in an attempt to more closely mimic
the events that naturally occur when T cells encounter antigen-
producing cells in order to produce an effective immune response.
Our data indicate that T lymphocytes derived from patients with
advanced colorectal cancer are able to mount effective, MHC-
independent, functional responses after transduction with CIR-
encoding recombinant retroviruses. Other studies have shown that
T lymphocytes isolated from patients with ovarian (Parker et al,
2000) and prostate (Gong et al, 1999) cancers are also susceptible
to retroviral transduction and CIR-mediated functional activity.
These studies together demonstrate that patient-derived T
lymphocytes are indeed suitable as vehicles for this type of gene
modification and that CIR technology is highly flexible through the
use of antibody recognition enabling virtually any protein antigen
to be targeted by T lymphocytes. However, it is also clear from this
work that a further understanding of CD3z-based CIR activities
and aspects of manipulated T lymphocyte biology, particularly
with respect to their function in vivo and the development of
practical GMP-based handling methods, are required to ensure
that this approach is fully adapted for clinical trial.
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